BioVie updates investors on its Alzheimer’s and Parkinson’s clinical programs
BioVie Inc (NASDAQ:BIVI) said it has made significant progress with its clinical programs, including its drug candidate NE3107 showing a clinically meaningful increase in motor control in patients with Parkinson’s disease who were treated with the drug for 28 days.
https://www.proactiveinvestors.com/companies/news/...ams-1000514.html
Moderation
Zeitpunkt: 13.12.22 11:44
Aktion: Forumswechsel
Kommentar: Sonstiges
Zeitpunkt: 13.12.22 11:44
Aktion: Forumswechsel
Kommentar: Sonstiges
Link: Nutzungsbedingungen